NicOx SA Enters €191.5 Million Partnership with Kowa for Global Rights to Glaucoma Treatment NCX 470

Reuters
17 Jul
NicOx SA Enters €191.5 Million Partnership with Kowa for Global Rights to Glaucoma Treatment NCX 470

NicOx SA, an international ophthalmology company, has announced a significant new partnership with Kowa Company, Ltd., a global pharmaceutical firm based in Japan. This agreement, valued at up to €191.5 million, grants Kowa exclusive rights to develop and commercialize NicOx's glaucoma treatment, NCX 470, in the U.S. and other territories worldwide, except for Japan, China, Korea, and Southeast Asia. The deal includes an upfront payment of €7.5 million to NicOx and potential development and commercial milestones contingent on the results of the Denali Phase 3 trial. Kowa will also cover the U.S. NDA filing costs and future development expenses. This collaboration marks a strategic expansion of NicOx's global reach and financial flexibility, allowing the company to explore further growth opportunities in the ophthalmology sector.

Disclaimer: This news brief was created by Public Technologies (PUBT) using generative artificial intelligence. While PUBT strives to provide accurate and timely information, this AI-generated content is for informational purposes only and should not be interpreted as financial, investment, or legal advice. NicOx SA published the original content used to generate this news brief via GlobeNewswire (Ref. ID: GNW1001118179-en) on July 17, 2025, and is solely responsible for the information contained therein.

Disclaimer: Investing carries risk. This is not financial advice. The above content should not be regarded as an offer, recommendation, or solicitation on acquiring or disposing of any financial products, any associated discussions, comments, or posts by author or other users should not be considered as such either. It is solely for general information purpose only, which does not consider your own investment objectives, financial situations or needs. TTM assumes no responsibility or warranty for the accuracy and completeness of the information, investors should do their own research and may seek professional advice before investing.

Most Discussed

  1. 1
     
     
     
     
  2. 2
     
     
     
     
  3. 3
     
     
     
     
  4. 4
     
     
     
     
  5. 5
     
     
     
     
  6. 6
     
     
     
     
  7. 7
     
     
     
     
  8. 8
     
     
     
     
  9. 9
     
     
     
     
  10. 10